Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 6/20 | 0.43 |
| ▸ | LDHA | P00338 | 2/20 | 0.41 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | BLVRB | P30043 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476171 | 0.90 | DHODH (0.49) | NR1I2P2RX3P2RX2DHODHLDHA | |
| SCHEMBL2170986 | 0.87 | NR1I2 (0.45) | NR1I2P2RX3P2RX2DHODHCTSA | |
| SCHEMBL3475350 | 0.85 | NR1I2 (0.42) | NR1I2P2RX3P2RX2DHODHLDHA | |
| SCHEMBL2171711 | 0.85 | CYP3A4 (0.46) | NR1I2P2RX3P2RX2DHODHMET | |
| SCHEMBL3057997 | 0.82 | P2RX3 (0.63) | NR1I2P2RX3P2RX2DHODHLDHA | |
| SCHEMBL2171503 | 0.81 | P2RX3 (0.43) | NR1I2P2RX3P2RX2CTSAMET | |
| SCHEMBL2171499 | 0.81 | P2RX3 (0.61) | NR1I2P2RX3P2RX2 | |
| SCHEMBL7947489 | 0.81 | P2RX3 (0.50) | NR1I2P2RX3P2RX2CTSA | |
| SCHEMBL1495762 | 0.80 | LDHA (0.50) | P2RX3P2RX2DHODHLDHACYP3A4 | |
| SCHEMBL2187309 | 0.80 | P2RX3 (0.56) | NR1I2P2RX3P2RX2CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2346825-A2 | MODULATORS OF P2X3 RECEPTOR ACTIVITY | Evotec AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | ADORA2B, IL1B, AVPR1B | NR1I2 400/4885P2RX3 207/4885P2RX2 240/4885 |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | NR1I2 461/4885P2RX3 219/4885P2RX2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.